logo

For the Inventor, By the Inventor

Reinach, Switzerland

Evolva Sa

USPTO Granted Patents = 69

% Expired Patents = 17.4



Trademarks = 6

Forward Citations = 417

Loading Chart...
Loading Chart...

144 inventors (with patents filed for the assignee):

goldMedal Jorgen Hansen (18 out of 21 patents)

silverMedal Jens Houghton-Larsen (15 out of 17 patents)

bronzeMedal Veronique Douchin (14 out of 15 patents)

4.  Michael Dalgaard Mikkelsen (14 out of 16 patents)

5.  Simon Carlsen (12 out of 13 patents)

6.  Kim Olsson (11 out of 11 patents)

7.  Ernesto Simon (11 out of 11 patents)

8.  Yaoquan Liu (9 out of 21 patents)

9.  Nina Nicoline Rasmussen (8 out of 9 patents)

10.  Michael Naesby (8 out of 9 patents)

11.  Louis Düring (7 out of 7 patents)

12.  Michael Katz (7 out of 9 patents)

13.  Angelika Semmler (6 out of 6 patents)

14.  Sathish Kumar (6 out of 7 patents)

15.  Muthuswamy Panchapagesa Murali (6 out of 6 patents)


Core Competencies:
Nootkatone
Steviol Glycosides
Mogroside Compounds
Terpenes
Biosynthesis
Recombinant Hosts
Microbial Fermentation
Enzymatic Synthesis
Phenylpropanoids
Resveratrol
Pinosylvin
Clavine-Type Alkaloids

69 patents:

1. 12709769 - METHODS FOR IMPROVED PRODUCTION OF REBAUDIOSIDE D AND REBAUDIOSIDE M (2026-08-18),
2. 11896008 - Use of nootkatone to treat mosquito infestations (2024-02-13),
3. 11821015 - Production of steviol glycosides in recombinant hosts (2023-11-21),
4. 11807888 - Production of steviol glycoside in recombinant hosts (2023-11-07),
5. 11800867 - Methods of repelling biting arthropods, reducing pathogen spread and treating arthropod infestation (2023-10-31),
6. 11737459 - Use of nootkatone to kill sap-sucking insects (2023-08-29),
7. 11530431 - Methods for improved production of Rebaudioside D and Rebaudioside M (2022-12-20),
8. 11466302 - Production of steviol glycosides in recombinant hosts (2022-10-11),
9. 11396669 - Production of steviol glycosides in recombinant hosts (2022-07-26),
10. 11248248 - Production of mogroside compounds in recombinant hosts (2022-02-15),
11. 11191266 - Methods and compositions for the treatment of infections and arthropod infestation (2021-12-07),
12. 11168343 - Production of steviol glycosides in recombinant hosts (2021-11-09),
13. 11155841 - Method for producing sphingoid base or sphingolipid (2021-10-26),
14. 11154057 - Use of nootkatone to treat mosquito infestations (2021-10-26),
15. 11136283 - Recovering and purifying resveratrol produced by microbial fermentation (2021-10-05),
Company Overview
Evolva SA, headquartered in Reinach, Switzerland, specializes in biosynthesis techniques to produce high-value ingredients through innovative microbial fermentation and enzymatic synthesis. The company focuses on developing natural compounds such as nootkatone, steviol glycosides, and mogroside compounds, leveraging recombinant hosts to enhance production efficiency. Evolva's commitment to sustainable practices positions it at the forefront of the biotechnology sector, addressing the growing demand for natural and sustainable alternatives in various industries.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

69 Patents

#5 in Reinach

#226 in Switzerland

#10,773 in the World

Reinach, CH
Reinach, Switzerland

Evolva Sa

Forward Citations = 417

144 inventors:

goldMedal Jorgen Hansen (18 out of 21 patents)

silverMedal Jens Houghton-Larsen (15 out of 17 patents)

bronzeMedal Veronique Douchin (14 out of 15 patents)

4.  Michael Dalgaard Mikkelsen (14 out of 16 patents)

5.  Simon Carlsen (12 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Evolva Sa. Retrieved from https://idiyas.com/company/evolva-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…